Treatment of Primary Sclerosing Cholangitis with Osteoporosis (Bone Mineral Density T-score ≤ −2.5) and Esophageal Varices

Clinical Scenario

This protocol addresses Primary sclerosing cholangitis (PSC) in patients who have developed osteoporosis — defined by a bone mineral density T-score of ≤ −2.5 — alongside a normal serum vitamin D level and concurrent esophageal varices.

Osteoporosis · T-score ≤ −2.5 Esophageal varices Normal serum vitamin D

Why Osteoporosis Matters Here

Osteoporosis in PSC is characterised by a bone mineral density T-score standard deviation of ≤ −2.5. The co-existence of esophageal varices is a clinically important factor that directly shapes the choice and delivery of bone-protective therapy in this population — distinguishing this scenario from straightforward osteoporosis management.

Management Approach

In PSC patients with established osteoporosis and a normal serum vitamin D level, management involves targeted supplementation combined with a bone-protective agent — the selection of which is guided by the patient's vascular comorbidities. The complete protocol is available below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1002/hep.32771

Osteoporosis: Characterized by bone mineral density T-score standard deviation ≤−2.5.
In patients with PSC with normal serum vitamin D levels who have osteopenia or osteoporosis, vitamin D (2000 IU/day) and calcium (1–1.5 g/day) supplementation should be administered.
Patients with osteoporosis should additionally receive bisphosphonate therapy orally or parenterally (in the presence of esophageal varices).

View source ↗